CuraTeQ Biologics receives positive opinion for biosimilar Dyrupeg from EMA
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
Subscribe To Our Newsletter & Stay Updated